Brief: Cymabay Therapeutics Long-Term Open Label Study Finds Treatment With Seladelpar For Two Years Improves Key Liver Biomarkers In Patients With PBC
15/11/2021 14:25
Nov 15 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY THERAPEUTICS LONG-TERM OPEN LABEL STUDY FINDS
TREATMENT
WITH SELADELPAR FOR TWO YEARS IMPROVES KEY LIVER BIOMARKERS IN
PATIENTS WITH PBC
Source text for Eikon: ID:nGNX8jnm23
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap